linjc16/ctgov huggingface dataset:
Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Study Overview
=================
Brief Summary
-----------------
To review the outcome of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005.

Detailed Description
-----------------
Chart review of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005 to determine outcome

Official Title
-----------------
Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Conditions
-----------------
Sarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with soft tissue sarcoma treated with chemotherapy form 2004 and 2005. Exclusion Criteria: Not Specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chart Review<br>patients diagnosed with soft tissue sarcoma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To Review the Outcome of Patients With Soft Tissue Sarcoma Treated With Chemotherapy From 2004 and 2005 |  | up to one year |
A Prospective Randomized Study Comparing Sentinel Lymph Node (SLN) Evaluation With Standard Pathological Evaluation for the Staging of Colon Carcinoma

Study Overview
=================
Brief Summary
-----------------
The objective of this trial is to define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping. Null hypothesis: There is no difference in the rate of lymph node metastasis between conventional histopathological processing of lymph nodes and SLN mapping with detailed pathologic examination using immunohistochemistry (IHC) in patients undergoing resection of colon carcinoma.

Conditions
-----------------
Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age Primary, non-metastatic [Stage I, II (localized, node negative), or III (localized, node positive)] colon carcinoma confirmed by tissue biopsy or colon mass clinically consistent with cancer and eventually confirmed by pathology Palpable mass at time of surgery Capable of providing informed consent Exclusion Criteria: Prior radiation or chemotherapy Non-palpable colon tumor Recurrent or Stage IV (metastatic) colon cancer Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Standard of Care<br>Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging | |
| Research<br>SOC with sentinel lymph node analysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Define the rate of upstaging of colon carcinoma lymph node metastasis with define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping |  | 1 day |
A Registry Study on Primary/Idiopathic Triglyceride Deposit Cardiomyovasculopathy

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to construct a registry; in order to understand the onset status of triglyceride deposit cardiomyovasculopathy (TGCV) in Japan with patients' background and natural history of the disease, and to explore disease-specific prognostic factors.

Official Title
-----------------
A Registry Study on Primary/Idiopathic Triglyceride Deposit Cardiomyovasculopathy

Conditions
-----------------
Triglyceride Deposit Cardiomyovasculopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients who have been conﬁrmed as TGCV based on the diagnostic criteria for TGCV Exclusion Criteria: The patients who refused to participate in the study by opt-out

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TGCV<br>Patients who have been confirmed as TGCV by a cardiologist. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The period between the date of TGCV diagnosis and the date of death due to any cause | The period is from the date of diagnosis of TGCV to the date of death due to any cause. Survival and lost follow-up cases will be censored on the final confirmation date of survival. | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Washout rate of BMIPP (%) |  | 10 years | 
| Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: LVEF (%) (UCG or QGS) |  | 10 years | 
| Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Any cardiovascular events |  | 10 years | 
| Presence (date of occurrence or treatment) or absence of various events | To measure the period from the date of diagnosis of TGCV to the date the following event occurs: non-fatal myocardial infarction by the outcome assessment, non-fatal stroke, hospitalization for heart failure, CABG, PCI, TVR, pacemaker/ICD implantation, CRT, VAD, acute coronary syndrome requiring hospitalization, hospitalization/device activation/heart transplantation due to fatal arrhythmia. However, surgery scheduled at the time of diagnosis will not be treated as an event. | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TGCV, triglyceride deposit cardiomyovasculopathy
Four Year Weight Change of Cornell Students

Study Overview
=================
Brief Summary
-----------------
Examining the effect of daily self-weighing on the ability of student to prevent from gaining weight during their four years at Cornell.

Detailed Description
-----------------
A group of freshman volunteers were randomly assigned to one of two groups. Both groups were given an internet based scale (Withings). The experimental group was asked to weigh themselves daily. The controls were asked to weigh themselves three times within one week every six months in response to being contacted by our researchers.

Conditions
-----------------
Weight Gain

Intervention / Treatment
-----------------
* Behavioral: Experimental


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>weigh themselves daily | Behavioral: Experimental<br>* Asked to weigh themselves<br>|
| Active Comparator: Control<br>Weigh themselves every six months | Behavioral: Experimental<br>* Asked to weigh themselves<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight | weight gain | 3 1/2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
among college students
Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques

Study Overview
=================
Brief Summary
-----------------
We hypothesize that patients who receive a supraclavicular block via Angiocath, placed intra-operatively and dosed post-operatively following neurologic examination, will have lower pain scores, lower use of intravenous morphine equivalents in the post-anesthesia care unit, and lower rates of intervention for post-operative nausea and vomiting. We also hypothesize that patients receiving this nerve block had the same rates of nerve damage as the patients who did not receive a block and that there will be no demonstrable safety concerns with this block.

Official Title
-----------------
Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques

Conditions
-----------------
Acute Pain, Pain, Postoperative

Intervention / Treatment
-----------------
* Procedure: Elbow Fracture Fixation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age under 18 Undergoing supracondylar fracture fixation in operating room Exclusion Criteria: Incomplete or inaccessable chart data

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: IV Opioids<br> | Procedure: Elbow Fracture Fixation<br> <br> |
| Active Comparator: Supraclavicular Single-Shot Block<br> | Procedure: Elbow Fracture Fixation<br> <br> |
| Active Comparator: Supraclavicular Catheter<br> | Procedure: Elbow Fracture Fixation<br> <br> |
| Active Comparator: Supraclavicular Angiocath<br> | Procedure: Elbow Fracture Fixation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative opioid use | Total doses | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-emetic drug use | Total doses | 24 hours | 
| Incidence of nerve damage or compartment syndrome | Evaluated by surgeon at follow up. | 1 month | 
| Pain Score | Using Visual Analog Scale and FLACC pain scale (for younger children) we will compare pain scores in the various groups. | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Supraclavicular Block, Supraclavicular Catheter, Pediatric Anesthesia, Regional Anesthesia, Supracondylar Elbow Fracture
Cardiovascular an Echocardiographic Assessment in Hypertension During Pregnancy

Study Overview
=================
Brief Summary
-----------------
Cardiovascular & echocardiographic assessment in pregnant women with hypertension during their pregnancy in comparison to Pregnant normotensive women.

Detailed Description
-----------------
Cardiovascular & echocardiographic assessment in pregnant women with hypertension during their pregnancy in comparison to Pregnant normotensive women. Also,comparing echocardiographic parameters in hypertensive pregnant women being treated with either alfa methyl dopa or labetolol.

Official Title
-----------------
Hypertension During Pregnancy: Cardiovascular & Echocardiographic Assessment: CREATION - P (01)

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hypertension during pregnancy: Chronic or pregnancy induced Exclusion Criteria: Inability to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control, normotensive, pregnancy<br>Control, normotensive, pregnancy | |
| hypertension, pregnancy, no treatment<br>hypertension, pregnancy, no treatment | |
| hypertension, pregnancy, drug treatment<br>hypertension, pregnancy, drug treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypertension impact on cardiovascular echocardiographic parameters and obstetric parameters in pregnant women with or without treatment |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome, Impact of alfa methyl dopa and labetolol on cardiovascular parameters in pregnant women |  | 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension Pregnancy
Anemia and Inflammation

Study Overview
=================
Brief Summary
-----------------
During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.

Official Title
-----------------
Interactive Effects of Iron Status and Inflammation on Serum Hepcidin and Erythrocyte Iron Incorporation in Young Women

Conditions
-----------------
Iron Deficiency Anemia, Inflammation

Intervention / Treatment
-----------------
* Biological: Dultavax and Vaxigrip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI <27.5kg/m2 body weight <70kg either non-anemic (Hb>12.5g/dl) or anemic (Hb between 8-12 g/dl and ferritin <15ng/ml) Exclusion Criteria: pregnant or lactating chronic disease smoking inflammation defined as CRP<5mg/L; AGP<1g/L

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-anemic women<br> | Biological: Dultavax and Vaxigrip<br>* All the women got an influenza/DTP vaccine in order to induce acute inflammation<br>|
| anemic women<br>anemia due to iron deficiency | Biological: Dultavax and Vaxigrip<br>* All the women got an influenza/DTP vaccine in order to induce acute inflammation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fractional and total iron absorption |  | 14 days after the second baseline test meal administration | 
| Fractional and total iron absorption |  | 14 days after the test meal administered 24 hours after vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum hepcidin |  | up to 36 hours | 
| Serum Interleukin 6 | inflammation | up to 36 hours | 
| Serum ferritin | Iron status | up to 36 hours | 
| Serum transferrin | Iron status | up to 36 hours | 
| Serum CRP | inflammation | up to 36 hours | 
| Serum AGP | inflammation | up to 36 hours |
Platelet Reactivity and MES During CEA

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze the association between aspirin efficacy and general platelet reactivity in relation to microembolic signals (MES) during carotid endarterectomy (CEA).

Official Title
-----------------
Platelet Reactivity Testing in Association With Perioperative Microembolic Signals During Carotid Endarterectomy

Conditions
-----------------
Carotid Artery Stenosis, Ischemic Stroke, Myocardial Infarction, Aspirin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Al patients undergoing elective carotid endarterectomy Exclusion Criteria: Patients requiring a blood transfusion prior to surgery Patients with an inappropriate temporal bone window for transcranial Doppler (TCD) Patients on vitamin K antagonists or antiplatelet treatment other then aspirin Patients with an artificial cardiac valve

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Carotid endarterectomy (CEA)<br>Patients undergoing carotid endarterectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microembolic signals (MES) | Microembolic signals detected by transcranial duplex (TCD) | During and 1 hour following carotid endarterectomy (CEA) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic stroke |  | within 30 days postoperative | 
| Asymptomatic perioperative myocardial injury | Troponin elevation > 0.1 ng/ml | 3 days postoperative | 
| Myocardial infarction |  | Within 30 days postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carotid endarterectomy, Transcranial doppler, Micro embolic signals, Platelets, Aspirin
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Study Overview
=================
Brief Summary
-----------------
This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Official Title
-----------------
A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

Conditions
-----------------
Diabetes Mellitus Type 2

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: taspoglutide
* Drug: taspoglutide
* Drug: taspoglutide
* Drug: taspoglutide
* Drug: taspoglutide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients, 18-75 years of age; type 2 diabetes mellitus, with stable metformin treatment for >=3 months; stable weight +/-10% for >=3 months before screening. Exclusion Criteria: type 1 diabetes mellitus; treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months; use of weight-lowering medications in the last 3 months; uncontrolled hypertension.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: taspoglutide<br>* 5mg sc weekly<br>|
| Experimental: 2<br> | Drug: taspoglutide<br>* 10mg sc weekly<br>|
| Experimental: 3<br> | Drug: taspoglutide<br>* 20mg sc weekly<br>|
| Experimental: 4<br> | Drug: taspoglutide<br>* 10mg sc every 2 weeks<br>|
| Experimental: 5<br> | Drug: taspoglutide<br>* 20mg sc every 2 weeks<br>|
| Placebo Comparator: 6<br> | Drug: Placebo<br>* sc weekly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change from baseline in HbAlc |  | Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change from baseline in FPG, fructosamine, body weight, fasting insulin, C-peptide, glucagon. |  | Week 8 | 
| Changes in lipid profile |  | Week 8 | 
| AEs, laboratory parameters, primary pharmacokinetic parameters |  | Throughout study |
The Changes of CD4+T Lymphocyte Subsets in Septic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the value of CD4+T lymphocyte subsets in cell immunity in the patients with sepsis.There are immunoparalysis in septic patients,the important player is the change of CD4+T lymphocyte,this immunoparalysis state contribute to the illness progress and outcome. Comprehend the change regularity of septic patients' cell immunity can guide fiter and correcter treatment.

Official Title
-----------------
The Role of CD4+T Lymphocyte Subsets in Cell Immunity in Patients With Sepsis

Conditions
-----------------
Sepsis, SIRS(Systemic Inflammatory Response Syndrome)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female aged 18 years old and over; Fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °C or lower than 36 °C (b)respiratory rate above 20/min, or PCO2 below 32 mmHg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than < 4,000/μl or less than 10% of bands. Clinically suspected infection; Exclusion Criteria: were under 18 years of age; were refused by the patients or his/her familiality; were suffering from acquired immunodeficiency syndrome,virlhepatitis,autoimmune diseases and hematology; use medicine which can affect immune system,such as Glucocorticoid and Immunosuppressant died within 24h after being taken into the ICU, or refused to get involved in the study, or gave up treatment during the period of observation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SIRS<br>(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells. | |
| sepsis<br>SIRS + infection | |
| Normal<br>not SIRS and have no infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CD4+T lymphocyte subsets, sepsis, immunoparalysis